371 related articles for article (PubMed ID: 25687192)
21. IL28B genetic variations are associated with treatment response of patients with chronic hepatitis C in a Chinese Han population.
Dong ZX; Zhou HJ; Xiang XG; Guo SM; Zhuang Y; Zhao GD; Xie Q
J Dig Dis; 2015 Feb; 16(2):90-7. PubMed ID: 25312023
[TBL] [Abstract][Full Text] [Related]
22. IL28B and IL10R -1087 polymorphisms are protective for chronic genotype 1 HCV infection and predictors of response to interferon-based therapy in an East-Central European cohort.
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Vincze A; Szereday L; Kisfali P; Melegh B
BMC Res Notes; 2014 Jan; 7():12. PubMed ID: 24398031
[TBL] [Abstract][Full Text] [Related]
23. Virological escape in HCV genotype-1-infected patients receiving daclatasvir plus ribavirin and peginterferon alfa-2a or alfa-2b.
McPhee F; Hernandez D; Zhou N; Yu F; Ueland J; Monikowski A; Chayama K; Toyota J; Izumi N; Yokosuka O; Kawada N; Osaki Y; Hughes EA; Watanabe H; Ishikawa H; Kumada H
Antivir Ther; 2014; 19(5):479-90. PubMed ID: 24448487
[TBL] [Abstract][Full Text] [Related]
24. IL28B polymorphisms, IP-10 and viral load predict virological response to therapy in chronic hepatitis C.
Fattovich G; Covolo L; Bibert S; Askarieh G; Lagging M; Clément S; Malerba G; Pasino M; Guido M; Puoti M; Gaeta GB; Santantonio T; Raimondo G; Bruno R; Bochud PY; Donato F; Negro F;
Aliment Pharmacol Ther; 2011 May; 33(10):1162-72. PubMed ID: 21443535
[TBL] [Abstract][Full Text] [Related]
25. Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
Chen MY; Liu CH; Chen TC; Su TH; Chen PJ; Chen DS; Kao JH; Liu CJ
J Gastroenterol Hepatol; 2014 Jan; 29(1):102-9. PubMed ID: 23829453
[TBL] [Abstract][Full Text] [Related]
26. Role of IL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment.
Boglione L; Cusato J; Allegra S; Cariti G; Di Perri G; D'Avolio A
Arch Virol; 2015 Aug; 160(8):2009-17. PubMed ID: 26060059
[TBL] [Abstract][Full Text] [Related]
27. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
[TBL] [Abstract][Full Text] [Related]
28. IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
Lindh M; Lagging M; Arnholm B; Eilard A; Nilsson S; Norkrans G; Söderholm J; Wahlberg T; Wejstål R; Westin J; Hellstrand K
J Viral Hepat; 2011 Jul; 18(7):e325-31. PubMed ID: 21692944
[TBL] [Abstract][Full Text] [Related]
29. [IL28B CC genotype: a protective factor and predictor of the response to interferon treatment in chronic hepatitis C virus infection].
Pár A; Pár G; Tornai I; Szalay F; Várszegi D; Fráter E; Papp M; Lengyel G; Fehér J; Varga M; Gervain J; Schuller J; Nemes Z; Péterfi Z; Tusnádi A; Hunyady B; Haragh A; Szinku Z; Pálinkás L; Berki T; Vincze A; Kisfali P; Melegh B
Orv Hetil; 2013 Aug; 154(32):1261-8. PubMed ID: 23916907
[TBL] [Abstract][Full Text] [Related]
30. Understanding the effect of the HCV polymerase inhibitor mericitabine on early viral kinetics in the phase 2 JUMP-C and PROPEL studies.
Chen YC; Bernaards C; Kulkarni R; Moreira S; Zhu Y; Chan A; Badman E; Ackrill A; Thommes J; Smith PF
Br J Clin Pharmacol; 2014 Sep; 78(3):533-42. PubMed ID: 24602156
[TBL] [Abstract][Full Text] [Related]
31. Interleukin-28b CC genotype predicts early treatment response and CT/TT genotypes predicts non-response in patients infected with HCV genotype 3.
Gupta AC; Trehanpati N; Sukriti S; Hissar S; Midha V; Sood A; Sarin SK
J Med Virol; 2014 Apr; 86(4):707-12. PubMed ID: 24415442
[TBL] [Abstract][Full Text] [Related]
32. Early viral kinetics during hepatitis C virus genotype 6 treatment according to IL28B polymorphisms.
Akkarathamrongsin S; Payungporn S; Thong VD; Poovorawan K; Prapunwattana P; Poovorawan Y; Tangkijvanich P
World J Gastroenterol; 2014 Aug; 20(30):10599-605. PubMed ID: 25132781
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 28B-related polymorphisms: a pathway for understanding hepatitis C virus infection?
Garcia RF; Moreira S; de Araújo Ramos AL; Ferreira LE; de Mattos AA; Tovo CV; Nader LA; Ramos JA; Rondinelli E; de Jesus Dominici A; Garcia CE; de Souza Leite Pinho M; Brandão-Mello CE; Villela-Nogueira CA; de França PH
World J Gastroenterol; 2013 Nov; 19(42):7399-404. PubMed ID: 24259970
[TBL] [Abstract][Full Text] [Related]
34. IL28B rs12980275 and HLA rs4273729 genotypes as a powerful predictor factor for rapid, early, and sustained virologic response in patients with chronic hepatitis C.
Sedighimehr P; Irani S; Sakhaee F; Vaziri F; Aghasadeghi M; Sadat SM; Jamnani FR; Fateh A; Siadat SD
Arch Virol; 2017 Jan; 162(1):181-189. PubMed ID: 27714501
[TBL] [Abstract][Full Text] [Related]
35. Predicting response to therapy in chronic hepatitis C: an approach combining interleukin-28B gene polymorphisms and clinical data.
Ladero JM; Martin EG; Fernández C; Carballo M; Devesa MJ; Martínez C; Suárez A; Díaz-Rubio M; Agúndez JA
J Gastroenterol Hepatol; 2012 Feb; 27(2):279-85. PubMed ID: 21722179
[TBL] [Abstract][Full Text] [Related]
36. Association between IL28B polymorphisms and first-phase viral load decrease in chronic hepatitis C virus-infected patients treated with peginterferon alfa-2b/ribavirin.
Arends JE; Fransen JH; Hoepelman AI; van Baarle D
Int J Antimicrob Agents; 2011 Dec; 38(6):538-9. PubMed ID: 21974859
[TBL] [Abstract][Full Text] [Related]
37. IL28B polymorphism genotyping as predictor of rapid virologic response during interferon plus ribavirin treatment in hepatitis C virus genotype 1 patients.
Rosso C; Abate ML; Ciancio A; Strona S; Caviglia GP; Olivero A; Touscoz GA; Rizzetto M; Pellicano R; Smedile A
World J Gastroenterol; 2014 Sep; 20(36):13146-52. PubMed ID: 25278709
[TBL] [Abstract][Full Text] [Related]
38. Low IL10 serum levels as key factor for predicting the sustained virological response to IFNα/ribavirin in Brazilian patients with HCV carrying IL28B CT/TT genotype.
Vasconcelos LR; Moura P; do Carmo RF; Pereira LB; Cavalcanti Mdo S; Aroucha DC; Dutra RA; Pereira LM
Hum Immunol; 2014 Aug; 75(8):895-900. PubMed ID: 24994464
[TBL] [Abstract][Full Text] [Related]
39. Prediction of sustained virologic response based on week 4 and week 12 response in hepatitis C virus genotype 1 patients treated with peginterferon and ribavirin: assessment in a favorable IL28B allele-prevalent area.
Chung HJ; Lee JW; Kim YS; Lee JI
Intervirology; 2013; 56(3):178-83. PubMed ID: 23306941
[TBL] [Abstract][Full Text] [Related]
40. Lead-in treatment with interferon-β/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype.
Itokawa N; Atsukawa M; Tsubota A; Kondo C; Hashimoto S; Fukuda T; Matsushita Y; Kidokoro H; Kobayashi T; Narahara Y; Nakatsuka K; Kanazawa H; Iwakiri K; Sakamoto C
J Gastroenterol Hepatol; 2013 Mar; 28(3):443-9. PubMed ID: 23173698
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
